AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Files An 8-K Results of Operations and Financial Condition

AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

On February 7, 2019, the Company issued a press release announcing that the Company will present its operational results for the fiscal second quarter 2019 on Thursday, February 7, 2019, at 9:00 a.m. ET. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibit is being filed herewith:

Exhibit

Description

Press Release dated February 7, 2019

AYTU BIOSCIENCE, INC Exhibit
EX-99.1 2 aytu_ex991.htm PRESS RELEASE Blueprint     Exhibit 99.1   Aytu BioScience Reports 71% Revenue Growth in Q2 FY19   Company Posts Highest Ever Quarterly Revenue   ENGLEWOOD,…
To view the full exhibit click here

About AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU)

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company also markets Primsol (trimethoprim hydrochloride), a trimethoprim-only oral solution for urinary tract infections. The Company’s pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men.

An ad to help with our costs